The present invention relates to a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, and kits and kits-of-part related thereto.

The present invention provides compounds of Formula I ##STR00001##
and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

The present invention provides compounds of Formula I ##STR00001##
and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Synergistic compositions of 4, 8, 12, and 13 medicinal components and various combinations thereof that provide multipath synergistic nutritional support for memory, cognition, and neuromuscular coordination in humans, cats, dogs, and horses and provide preventive treatments for various neurological diseases. The composition including a mixture of Astragalus membranaceus (Huang Qi) roots, gastrodia elata tuber, Vaccinium uliginosum berries, L-Theanine, Genistein, Berberine, Schisandra chinensis berry extract, lithium, selenium, piperine, Methyl Folate, and Astragaloside IV.

Synergistic compositions of 4, 8, 12, and 13 medicinal components and various combinations thereof that provide multipath synergistic nutritional support for memory, cognition, and neuromuscular coordination in humans, cats, dogs, and horses and provide preventive treatments for various neurological diseases. The composition including a mixture of Astragalus membranaceus (Huang Qi) roots, gastrodia elata tuber, Vaccinium uliginosum berries, L-Theanine, Genistein, Berberine, Schisandra chinensis berry extract, lithium, selenium, piperine, Methyl Folate, and Astragaloside IV.

The present invention relates to methods and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates to a method of treating fibrosis in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor.

The present invention relates to methods and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates to a method of treating fibrosis in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor.

Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.